Tapsi Kumar, PhD

2.5K posts

Tapsi Kumar, PhD banner
Tapsi Kumar, PhD

Tapsi Kumar, PhD

@TapsiKS

BMS | ExChair - Scholarships @Awis_Houston | PHD @MDAndersonNews. Single cell genomics | Computational Biologist | Oncology. Crazy animal (-reptile) lover.

Cambridge, MA Katılım Mart 2014
661 Takip Edilen391 Takipçiler
Tapsi Kumar, PhD retweetledi
Ming "Tommy" Tang
Ming "Tommy" Tang@tangming2005·
Claude Chat vs Cowork vs Code Tab vs Code CLI — what's actually different? I used Claude Code to fact-checked every feature against official Anthropic docs and put together this comparison table.
Ming "Tommy" Tang tweet media
English
2
5
19
2.2K
Tapsi Kumar, PhD retweetledi
Nav Toor
Nav Toor@heynavtoor·
BREAKING: AI can now analyze any stock like a Wall Street analyst (for free). Here are 10 insane Claude prompts that replace $2,000/month Bloomberg terminals (Save for later)
Nav Toor tweet media
English
12
83
494
71.3K
Tapsi Kumar, PhD retweetledi
Vivek Subbiah, MD
Vivek Subbiah, MD@VivekSubbiah·
Wow! Cool--> #PrecisionMedicine in action 👉Individualized mRNA vaccines evoke durable T cell immunity in adjuvant Triple-negative breast cancer #TNBC @Nature @OncoAlert 👉Individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy 👉11/14 patients remained relapse-free for up to six years post-vaccination. nature.com/articles/s4158…
Vivek Subbiah, MD tweet media
English
1
17
36
3.3K
Tapsi Kumar, PhD retweetledi
Nav Toor
Nav Toor@heynavtoor·
🚨BREAKING: Claude is insane for market research. I reverse-engineered how top consultants at McKinsey, Goldman Sachs, & JP Morgan use it. The difference is night and day. Here are 12 insane Claude Opus 4.6 prompts they don't want you to know (Save for later)
Nav Toor tweet media
English
13
70
450
134K
Tapsi Kumar, PhD retweetledi
Prof Jeffrey S Morris
Prof Jeffrey S Morris@jsm2334·
Important information to keep in mind. AI is an incredible tool to supplement your work but don’t use it as a substitute for thinking for yourself .. or you atrophy the parts of your brain used for thinking for yourself.
Next Science@NextScience

🧠 MIT recently completed the first brain-scan study on ChatGPT users—and the results are deeply revealing. Rather than boosting brain function, prolonged AI use may be dulling it. Over four months of cognitive data suggest we might be measuring productivity all wrong ⤵️ In MIT’s study, participants had their brains scanned while using ChatGPT. → 83.3% of users couldn’t recall a single sentence they’d written just minutes earlier. → In contrast, those writing without AI had no trouble remembering. Brain connectivity dropped sharply—from 79 to 42 points. → That’s a 47% drop in neural engagement. → The lowest cognitive performance among all user groups. Even after stopping ChatGPT use in later sessions, these users showed continued under-engagement. → Their performance remained lower than those who never used AI. → This suggests more than dependency—it’s cognitive weakening. Beyond the scans, educators flagged the writing itself. → Essays were technically solid, but often called “robotic,” “soulless,” and “lacking depth.” Here’s the paradox: → ChatGPT makes you 60% faster at completing tasks… → But it reduces the mental effort required for learning by 32%. The top-performing group? → Those who began without AI and added it later. → They retained the best memory, brain activity, and overall scores. Using ChatGPT can feel empowering—but it may quietly offload your thinking. → You gain speed, but lose engagement. → You get answers, but stop learning how to think. The takeaway isn’t to avoid AI—but to use it intentionally. → Use it to assist, not replace your mind. → Build cognitive strength—not dependency. MIT’s early study on AI and the brain lays out the stakes. The way we use these tools matters more than ever.

English
5
4
20
2.3K
Tapsi Kumar, PhD retweetledi
Python Programming
Python Programming@PythonPr·
Top 5 Types of AI Agents!
Python Programming tweet media
English
9
64
283
9.2K
Tapsi Kumar, PhD retweetledi
Naoto T Ueno, MD, PhD
Naoto T Ueno, MD, PhD@teamoncology·
Tumors resistant to one ADC can regain sensitivity to another ADC with a different payload. Our work shows payload choice—not just target expression—may extend clinical benefit in breast cancer. No evidence that sequential of FDA approved drugs are beneficial in the clinical setting. pubmed.ncbi.nlm.nih.gov/41591991/
Naoto T Ueno, MD, PhD tweet media
English
5
38
95
8.3K
Tapsi Kumar, PhD retweetledi
Akshay 🚀
Akshay 🚀@akshay_pachaar·
Google just dropped another banger! the figures in this paper were drawn by the system described in the paper. PaperBanana is an agentic framework that generates publication-ready academic illustrations from methodology descriptions. no manual design, no Figma, just your method section and a caption. here's how it works: five specialized agents collaborate in sequence: > Retriever: finds relevant reference diagrams from a curated set of NeurIPS papers. matches by visual structure, not topic. > Planner: translates your methodology text into a detailed visual description using in-context learning. > Stylist: applies aesthetic guidelines (color palettes, typography, layout) auto-summarized from hundreds of top-tier papers. > Visualizer + Critic loop: generates the image, critiques it against source text, and refines. repeats for 3 rounds. one surprising finding: randomly selected examples work nearly as well as semantically matched ones. what matters is showing the model what good diagrams look like, not finding the topically perfect reference. in blind evaluations, humans preferred PaperBanana outputs nearly 3 out of 4 times. it also extends to statistical plots using code-based generation for numerical precision. link in the next tweet.
Akshay 🚀 tweet media
English
48
450
2.2K
227.3K
Tapsi Kumar, PhD retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
This is possibly the most controversial finding in immuno-oncology. The effect size is hard to believe. Though RCTs are hard NOT to believe. We need a coordinated effort between academia & pharma to look back at prior RCTs to investigate this. For the safety of our patients.
Eric Topol@EricTopol

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system nature.com/articles/s4159…

English
32
83
749
112.4K
Tapsi Kumar, PhD retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Important to learn more about resistance to antibody drug conjugates. Report @CD_AACR on paired biopsies pre/post T-DXd show 49% had decrease in HER2 expression (half of those with complete loss) and others had point mutations. Can rational combos help? aacrjournals.org/cancerdiscover…
English
1
15
44
3.6K
Tapsi Kumar, PhD retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
I’m pleased to share the results of our first meta-analysis of 2026 📌In ~7,000 pts, pCR rates were significantly higher in HER2 IHC 3+ tumors compared with HER2 2+/ISH+, regardless of single or dual anti-HER2 NACT 💬ADC data were not included, but DB-11 suggests the same biological gradient cancertreatmentreviews.com/article/S0305-…
Yakup Ergün tweet mediaYakup Ergün tweet media
English
0
20
76
4.4K
Tapsi Kumar, PhD retweetledi
Diego A. Díaz-García
Diego A. Díaz-García@diegoadiazg·
🎯 ADCs in cancer: molecular and immune drivers. 🔹Efficacy and toxicity of antibody–drug conjugates depend on antibody, linker, payload, and tumor microenvironment. 🔹Beyond cytotoxicity, immunogenic cell death, dendritic cell activation, and Fc interactions amplify clinical benefit and support rational combinations with immunotherapy. 📖 @NatureRevCancer DOI 👉🏻 10.1038/s41568-025-00869-w #CánCare #oncology #ADC #molecularoncology
Diego A. Díaz-García tweet mediaDiego A. Díaz-García tweet mediaDiego A. Díaz-García tweet media
English
4
21
70
3K
Tapsi Kumar, PhD retweetledi
Science News
Science News@SciencNews·
The Immune Response
Science News tweet media
English
3
223
776
34.8K
Tapsi Kumar, PhD retweetledi
Anirban Maitra
Anirban Maitra@Aiims1742·
“we found that 49% cases had major decreases in HER2 expression at progression, and among them, 52% exhibited complete HER2 loss.” 🤯 Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding aacrjournals.org/cancerdiscover…
Anirban Maitra tweet media
English
5
27
86
7.6K
Tapsi Kumar, PhD retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
When I moved to the US in 2021, breast oncology was very different. With 2025 coming to an end, I decided to look back and review 10 major milestones in BC medical oncology care we saw over the past 5 years. With hope and expectation to see so much more unfolding over the next 5!
Paolo Tarantino tweet media
English
4
64
193
37.8K
Tapsi Kumar, PhD retweetledi
Naoto T Ueno, MD, PhD
Naoto T Ueno, MD, PhD@teamoncology·
It's truly exciting to see progress with ADC. As many ADC applications move into the early breast cancer setting, a major challenge is figuring out how to overcome resistance. Currently, we haven't identified a clear resistance mechanism, nor do we have a solid preclinical or clinical understanding of how to address this resistance. Our success has resulted in a major headache.
Paolo Tarantino@PTarantinoMD

2025: quite a year for ADCs in breast cancer • T-DXd approved for 1L cytotoxic tx of HR+/HER2-low (& #ultralow) MBC • T-DXd now also approved for 1L HER2+ MBC • First ph3 data of T-DXd in the CURATIVE setting • Two TROP2 ADCs replaced 1L SoC in mTNBC Keep ’em coming, 2026🎯

English
0
7
23
4.3K